Dr. Kenneth Carter, Chief Development Officer at Miletus Biotechnology, is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development. He has been involved in starting several biotechnology and biopharma service companies as a co-founder, advisor, CEO, chairman, and board member.

Dr. Carter currently advises or serves on the board of directors for several companies, including Mayflower (a partnership between Mayo Clinic and Hibiscus Bioventures), Iterion Pharmaceuticals, and Noble Life Sciences. He also serves as CEO of Noble Life Sciences, Chairman of Black Canyon Bion, and board supervisor for Thermo Fisher Hanzhou LTD, a joint venture between Thermo Fisher and Innoforce.

Previously, Dr. Carter was co-founder and CEO of Avalon Pharmaceuticals (now part of Abbvie) and co-founder, chairman and CEO of NexImmune. Under his leadership, both companies developed a pipeline of cancer drug candidates based on groundbreaking technology and completed IPOs and listing on the NASDAQ Stock Market.

Dr. Carter has also been instrumental in the early-stage development of several biopharma services companies, including Noble Life Sciences, Innoforce, Cytotest, and NeoDiagnostix.

Earlier in his career, Dr. Carter was head of gene mapping at Human Genome Sciences Inc. (now part of GlaxoSmithKline), where he was involved in the discovery of dozens of novel human genes and proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer.

Dr. Carter is also engaged in a range of educational and teaching activities, including at Johns Hopkins University, where for several years he taught a course entitled “Creating a Biotechnology Enterprise.” He has served on boards of several not-for-profit organizations, including BIO, the world’s largest biotechnology industry organization.